Navigation Links
BIOCOM Announces Endorsement in 52nd Congressional District Race
Date:9/6/2012

SAN DIEGO, Sept. 6, 2012 /PRNewswire/ -- BIOCOM, the association for the Southern California life science community, today announced the endorsement of Congressman Brian Bilbray for Congress in the newly drawn 52nd District, which includes a large portion of the northern section of the City of San Diego, as well as the cities of Coronado and Poway.

"Representative Bilbray's record in Congress has been one of unparalleled support for the life science industry, one of San Diego County's main economic drivers," said Joe Panetta, President and CEO of BIOCOM.  "From support of basic research to helping to reform the FDA so patients can get access to life-saving treatments earlier to supporting the emerging field of biorenewables, Congressman Brian Bilbray has been a champion of the life sciences industry and of San Diego.  In fact, Brian was BIOCOM's 2011 Legislator of the Year for all of his efforts on behalf of the industry.   He has also repeatedly shown the ability and leadership to reach across the aisle to accomplish things in a bipartisan manner.  BIOCOM is very proud to support him."

Congressman Bilbray holds a coveted seat on the important House Energy and Commerce Committee, a committee where the issues most important to the life science community are generally first heard. Congressman Bilbray has also worked with BIOCOM on the Prescription Drug and Medical Device User Fee Acts reauthorizations that were enacted as part of the Food and Drug Administration Safety and Innovation Act of 2012.  Congressman Bilbray specifically worked with BIOCOM on insuring there was a pathway of accelerated review for breakthrough therapies and a clear process for low risk medical devices to be reviewed and approved ("de-novo"), two subjects that were at risk of not being included in the final legislation.

Congressman Bilbray also introduced legislation which would repeal the medical device tax adopted as part of the Affordable Care Act; because it is based solely on receipts, this tax threatens many small and mid size medical device companies which are barely profitable or not yet profitable.  Additionally,  the Congressman has been an outspoken supporter of consistent funding for the National Institutes of Health (NIH), and was responsible for bringing NIH Director Francis Collins to San Diego for an interactive meeting with stakeholders.

About BIOCOM

BIOCOM is one of the largest regional life science associations in the world, representing more than 560 member companies in Southern California. The association focuses on initiatives that position the region's life science industry competitively on the world stage, and on the development and delivery of innovative products that improve health and quality of life. For more information on BIOCOM or the Southern California biotechnology and medical device community, please visit the organization's Web site at http://www.biocom.org or call (858) 455-0300.


'/>"/>
SOURCE BIOCOM
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):